Claims
- 1. A method of increasing synthesis or secretion of a growth factor protein by a RPE cell, the method comprising the steps of:
(a) providing a RPE cell; and (b) transducing said cell with an expression vector comprising a growth factor-encoding nucleic acid in an amount effective to increase synthesis or secretion of said growth factor protein.
- 2. The method of claim 1, wherein said growth factor protein is selected from the group consisting of IGF-1, bFGF, aFGF, CNTF, PDGF, and BDNF.
- 3. The method of claim 1, wherein said growth factor protein is human IGF-1.
- 4. The method of claim 1, wherein said growth factor protein is a fusion protein.
- 5. The method of claim 4, wherein said fusion protein comprises an epitope tag.
- 6. The method of claim 5, wherein said fusion protein comprises a His6 tag.
- 7. The method of claim 6, wherein said fusion protein is His6-tagged human IGF-1.
- 8. The method of claim 4, wherein said fusion protein comprises a reporter protein.
- 9. The method of claim 8, wherein said reporter protein is selected from the group consisting of GFP, luciferase and β-galactosidase.
- 10. The method of claim 8, wherein said fusion protein is IGF-1 tagged with GFP.
- 11. The method of claim 1, wherein said gene expression vector comprises an inducible promoter.
- 12. An expression vector comprising a growth factor-encoding nucleic acid, wherein said vector directs the production of an expressed growth factor fusion protein.
- 13. The vector of claim 12, wherein the fusion protein comprises human IGF-1.
- 14. The vector of claim 12, wherein the vector is a plasmid.
- 15. A kit for gene transduction of a cell, said kit comprising at least one expression vector comprising a nucleic acid encoding a human growth factor protein fused with a reporter protein, or a nucleic acid encoding a human growth factor protein fused with an epitope tag, and instructions for use.
- 16. The kit of claim 15, wherein the at least one expression vector directs expression of a human IGF-1 protein linked to GFP reporter protein.
- 17. The kit of claim 15, wherein the at least one expression vector directs expression of a human IGF-1 protein linked to a His6 epitope tag.
- 18. A retinal cell transduced with the vector of claim 12.
- 19. The transduced retinal cell of claim 18, wherein the cell is a RPE cell.
- 20. The cell of claim 19, wherein said cell is a human cell.
- 21. A method of treating dysfunction or injury of a RPE cell, said method comprising transducing said cell with an expression vector that expresses a growth factor protein in an amount sufficient to improve or cure said dysfunction or injury.
- 22. The method of claim 21, wherein the dysfunction affecting the RPE cell is caused by cancer, viral infection, diabetes, hereditary RPE dystrophy, AMD, retinitis pigmentosa, or drug-induced toxicity.
- 23. The method of claim 21, wherein the dysfunction affecting the RPE comprises inability to divide, or commitment to programmed cell death.
- 24. The method of claim 21, wherein said injury of the RPE cells is caused by abrasions, ocular trauma, surgical and laser procedures, or retinal detachment.
- 25. A method of treating a retinal disease or condition, said method comprising the steps of:
(a) providing a subject having or at risk for developing a retinal disease or condition; (b) providing an expression vector comprising a growth factor-encoding nucleic acid; and (c) administering to said subject an amount of said vector sufficient to ameliorate or cure said disease.
- 26. The method of claim 25, wherein the retinal disease or condition is selected from the group consisting of cancer, viral infection, diabetic retinopathy, hereditary RPE dystrophy, AMD, retinitis pigmentosa, drug-induced toxicity, macular commotio, surgical injury, and laser-induced injury.
- 27. The method of claim 20, wherein said growth factor is human IGF-1.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Application Serial No. 60/367,873 filed Mar. 27, 2002. The foregoing is incorporated herein by reference.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with U.S. government support under grant number K08 EY00381 awarded by the National Institutes of Health. The U.S. government may have certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60367873 |
Mar 2002 |
US |